Mometasone furoate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Mometasone furoate
Accession Number
DB14512  (DBSALT002454)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[Label][5, 6]. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well[2]. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[Label][5, 6].

Structure
Thumb
Synonyms
  • Mometasone furoate
  • Mometasone furoate anhydrous
External IDs
SCH 32088 / SCH-32088
Product Ingredients
IngredientUNIICASInChI Key
Mometasone furoate monohydrateMTW0WEG809141646-00-6AQCCVUHZMIMSIB-HRVPQZBTSA-N
Active Moieties
NameKindUNIICASInChI Key
Mometasoneprodrug8HR4QJ6DW8105102-22-5QLIIKPVHVRXHRI-CXSFZGCWSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AsmanexInhalant220 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2006-03-09Not applicableUs
AsmanexInhalant110 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2005-03-30Not applicableUs
AsmanexInhalant220 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2005-03-30Not applicableUs
Asmanex HFAAerosol100 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2014-04-25Not applicableUs
Asmanex HFAAerosol200 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2014-04-25Not applicableUs
Asmanex TwisthalerPowder100 mcgRespiratory (inhalation)Merck Ltd.2015-04-08Not applicableCanada
Asmanex TwisthalerPowder200 mcgRespiratory (inhalation)Merck Ltd.2011-12-21Not applicableCanada
Asmanex TwisthalerPowder400 mcgRespiratory (inhalation)Merck Ltd.2011-12-21Not applicableCanada
Elocom CreamCream0.1 %TopicalMerck Ltd.1991-12-31Not applicableCanada
Elocom LotionLotion0.1 %TopicalMerck Ltd.1991-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mometasoneSpray, metered50 mcgNasalApotex Corporation2013-03-25Not applicableCanada
Mometasone FuroateCream1 mg/1gTopicalREMEDYREPACK INC.2019-03-29Not applicableUs
Mometasone FuroateOintment1 mg/1gTopicalPerrigo New York Inc2008-07-18Not applicableUs
Mometasone FuroateCream1 mg/1gTopicalProficient Rx LP2007-04-18Not applicableUs
Mometasone FuroateOintment1 mg/1gTopicalRebel Distributors2006-10-18Not applicableUs
Mometasone FuroateCream1 mg/1gTopicalGw Pharmaceuticals Ltd.2006-08-23Not applicableUs
Mometasone FuroateSolution1 mg/1mLTopicalPerrigo New York Inc2008-12-11Not applicableUs
Mometasone FuroateCream1 mg/1gTopicalPerrigo New York Inc.2004-12-21Not applicableUs
Mometasone FuroateSpray, metered50 ug/1NasalAmneal Pharmaceuticals2017-04-04Not applicableUs
Mometasone FuroateCream1 mg/1gTopicalNucare Pharmaceuticals,inc.2006-08-23Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MosaspraySpray, metered50 mcgNasalSandoz Canada IncorporatedNot applicableNot applicableCanada
Nasal Allergy and Congestion ReliefSpray, metered50 mcgNasalApotex CorporationNot applicableNot applicableCanada
Nasonex Allergy and CongestionSpray, metered50 mcgNasalMerck Ltd.Not applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DuleraMometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)Merck Sharp & Dohme Corp.2010-06-22Not applicableUs
DuleraMometasone furoate (100 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)Merck Sharp & Dohme Corp.2010-06-22Not applicableUs
DuleraMometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)A-S Medication Solutions2010-06-22Not applicableUs
ZenhaleMometasone furoate (50 mcg) + Formoterol fumarate (5 mcg)Aerosol, meteredRespiratory (inhalation)Merck Ltd.2011-06-20Not applicableCanada
ZenhaleMometasone furoate (200 mcg) + Formoterol fumarate (5 mcg)Aerosol, meteredRespiratory (inhalation)Merck Ltd.2011-06-17Not applicableCanada
ZenhaleMometasone furoate (100 mcg) + Formoterol fumarate (5 mcg)Aerosol, meteredRespiratory (inhalation)Merck Ltd.2011-03-10Not applicableCanada
Categories
UNII
04201GDN4R
CAS number
83919-23-7
Weight
Average: 521.429
Monoisotopic: 520.141944106
Chemical Formula
C27H30Cl2O6
InChI Key
WOFMFGQZHJDGCX-ZULDAHANSA-N
InChI
InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
IUPAC Name
(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-chloro-1-(2-chloroacetyl)-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl furan-2-carboxylate
SMILES
[H][C@@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@]([H])(O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)CCl

Pharmacology

Indication

There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients ≥4 years[Label]. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years, treating nasal polyps in patients ≥18 years, and prophylaxis of seasonal allergic rhinitis in patients ≥12 years[5]. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years[6].

Associated Conditions
Pharmacodynamics

Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of dexamethasone[2]. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action[2]. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammation[Label][1, 2, 3, 5, 6].

Mechanism of action

In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes[3]. There is also evidence of inhibition of histamine, leukotrienes, and cytokines[3].

Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity[2]. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of dexamethasone[2]. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus[3]. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5)[3]. Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB)[2, 3].

TargetActionsOrganism
AGlucocorticoid receptorNot AvailableHumans
UProgesterone receptorNot AvailableHumans
Absorption

The mean time to peak concentration is 1.0 to 2.5 hours[Label]. Bioavailability has been reported as <1%[Label] but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%[3]. The 0.1% ointment may have a bioavailability of 0.7%[6].

Volume of distribution

Steady state volume of distribution of 152L[Label].

Protein binding

98% to 99% (in vitro concentration of 5 to 500ng/mL)[Label][5].

Metabolism

Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolites[Label][5, 1, 3]. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate[1, 3, 4].

Route of elimination

For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine[Label][5].

Half life

The terminal half life of an inhaled dose is approximately 5 hours[Label] though it has been reported as 5.8 hours by other sources[5, 2].

Clearance

The clearance rate of mometasone furoate is not readily available[1], though it may be close to 90L/h[2].

Toxicity

Overdose with a mometasone furoate inhaler may occur with chronic overuse[Label][5]. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoring[Label][5].

In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humans[Label][5, 6]. The benefits and risks of use should be considered in pregnant patients[5, 6]

It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothers[Label][5, 6].

Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatment[Label]. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalers[Label].

A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoate[Label][5, 6].

The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severity[Label][5].

The effects of mometasone furoate in renal impairment, and across gender and race have not been studied[Label][5].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Mometasone furoate.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Mometasone furoate.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Mometasone furoate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Mometasone furoate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Mometasone furoate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Mometasone furoate.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Mometasone furoate.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Mometasone furoate.
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Mometasone furoate.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Mometasone furoate.
Food Interactions
Not Available

References

General References
  1. Szefler SJ: Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S26-31. [PubMed:11449203]
  2. Hubner M, Hochhaus G, Derendorf H: Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005 Aug;25(3):469-88. doi: 10.1016/j.iac.2005.05.004. [PubMed:16054538]
  3. Crim C, Pierre LN, Daley-Yates PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001 Sep;23(9):1339-54. [PubMed:11589253]
  4. Teng XW, Cutler DJ, Davies NM: Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos. 2003 Nov;24(8):321-33. doi: 10.1002/bdd.362. [PubMed:14595701]
  5. Mometasone Furoate Nasonex FDA Label [File]
  6. Mometasone Furoate Elocon FDA Label [File]
External Links
KEGG Compound
C07817
ChemSpider
390091
BindingDB
50148733
ChEBI
47564
ChEMBL
CHEMBL1161
HET
MOF
Wikipedia
Mometasone_furoate
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
PDB Entries
1sr7 / 4e2j / 4p6w
FDA label
Download (609 KB)
MSDS
Download (185 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAsthma Bronchial1
3CompletedTreatmentChronic Rhinosinusitis / Nasal Polyposis1
3CompletedTreatmentRhinitis, Allergic, Seasonal3
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4Not Yet RecruitingOtherHypothyroidism1
4Not Yet RecruitingTreatmentAllergic Rhinosinusitis / Chronic Eosinophilic Rhinosinusitis / Chronic Rhinosinusitis (Diagnosis)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InhalantRespiratory (inhalation)110 ug/1
InhalantRespiratory (inhalation)220 ug/1
AerosolRespiratory (inhalation)100 ug/1
AerosolRespiratory (inhalation)200 ug/1
PowderRespiratory (inhalation)100 mcg
PowderRespiratory (inhalation)200 mcg
PowderRespiratory (inhalation)400 mcg
AerosolRespiratory (inhalation)
CreamTopical0.1 %
LotionTopical0.1 %
OintmentTopical0.1 %
CreamTopical1 mg/1g
OintmentTopical1 mg/1g
CreamTopical1 g/100g
LotionTopical1 mg/1mL
LotionTopical1 mg/1g
OintmentTopical1 mg/1
SolutionTopical1 mg/1mL
Spray, meteredNasal50 ug/1
Spray, meteredNasal50 mcg
CreamTopical.1 %
LotionTopical.1 %
ImplantIntrasinal1350 ug/1
Aerosol, meteredRespiratory (inhalation)
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6127353Yes2000-10-032018-04-03Us
US6240918Yes2001-06-052017-08-20Us
US8173172Yes2012-05-082018-09-17Us
US6503537Yes2003-01-072018-09-17Us
US5829434Yes1998-11-032016-05-03Us
US6068832No2000-05-302017-08-27Us
US7067502No2006-06-272020-05-21Us
US7566705No2009-07-282020-05-21Us
US8109918No2012-02-072024-03-12Us
US7951131No2011-05-312024-03-12Us
US8025635No2011-09-272027-06-12Us
US9585681No2017-03-072026-04-04Us
US7951130No2011-05-312024-03-12Us
US7544192No2009-06-092026-11-29Us
US7951133No2011-05-312024-03-12Us
US7713255No2010-05-112024-03-12Us
US7662141No2010-02-162024-03-12Us
US8763222No2014-07-012032-02-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)215-228Not Available
water solubilityInsolubleNot Available
logP4.115Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0108 mg/mLALOGPS
logP4.27ALOGPS
logP5.06ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.81 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity132.5 m3·mol-1ChemAxon
Polarizability52.57 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03mj-3891000000-64a4294ec7bf5ac82d6c

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Furoic acid esters / Alpha-chloroketones / Heteroaromatic compounds / Secondary alcohols
show 10 more
Substituents
Progestogin-skeleton / 20-oxosteroid / Steroid ester / Halo-steroid / Hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / Oxosteroid / 11-hydroxysteroid
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, 11beta-hydroxy steroid, steroid ester, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 2-furoate ester (CHEBI:47564)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5. [PubMed:8439518]
  2. Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
  3. Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60. [PubMed:9793625]
  4. Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34. [PubMed:12127907]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Mometasone Furoate Twisthaler Label [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. [PubMed:15189034]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Berger WE, Milgrom H, Chervinsky P, Noonan M, Weinstein SF, Lutsky BN, Staudinger H: Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol. 2006 Nov;97(5):672-80. doi: 10.1016/S1081-1206(10)61099-X. [PubMed:17165278]
  2. Sharpe M, Jarvis B: Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61(9):1325-50. [PubMed:11511026]

Drug created on July 12, 2018 09:10 / Updated on April 19, 2019 16:00